Researchers treating patients with advanced/metastatic non–small cell lung cancer participated in the TROPION-Lung01 global phase III study. Of the participants, 299 received Dato-DXd and 305 received docetaxel.
In the overall trial population, Dato-DXd increased overall survival by 1.1 months. For patients with nonsquamous histology, survival increased by 2.3 months.
For patients with nonsquamous histology and actionable genomic alterations, Dato-DXd increased survival by 5.8 months. For patients with nonsquamous histology and no actionable genomic alterations, Dato-DXd increased survival by 1.3 months.
While the results showed a numerical benefit, they also showed Dato-DXd had no statistically significant effect on overall survival, the study authors wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
